A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

Transfusion

Volumn 50, Issue 11, 2010, Pages 2362-2375

  Goodrich, Raymond P ^a  

^a CaridianBCT Biotechnologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOIMMUNIZATION; APHERESIS; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; BACTERIAL INFECTIONS; BLOOD PLATELETS; BLOOD PRESERVATION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PLATELET TRANSFUSION; RIBOFLAVIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 78349271162     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02694.x     Document Type: Article

References (49)

1. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F,. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338 -47.
2. Dodd R, Roth WK, Ashford P, Dax EM, Vyas G,. Transfusion medicine and safety. Biologicals 2009; 37: 62 -70.
3. Seghatchian J, De Sousa G,. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189 -96.
4. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L,. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423 -35.
5. Ben-Hur E, Horowitz B,. Advances in photochemical approaches for blood sterilization. Photochem Photobiol 1995; 62: 383 -8.
6. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H,. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60: 207 -13.
7. Wagner SJ, Skripchenko A, Robinette D, Foley JW, Cincotta L,. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem Photobiol 1998; 67: 343 -9.
8. Matthews JL, Sogandares-Bernal F, Judy MM, Marengo-Rowe AJ, Leveson JE, Skiles H, Newman JT, Chanh TC,. Preliminary studies of photoinactivation of human immunodeficiency virus in blood. Transfusion 1991; 31: 636 -41.
9. Matthews JL, Newman JT, Sogandares-Bernal F, Judy MM, Skiles H, Leveson JE, Marengo-Rowe AJ, Chanh TC,. Photodynamic therapy of viral contaminants with potential for blood banking applications. Transfusion 1988; 28: 81 -3.
10. Li J, De KD, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP,. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82 -90.
11. Van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, De Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L,; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426 -33.
12. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534 -41.
13. Goodrich RP, Edrich RA, Li J, Seghatchian J,. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5 -17.
14. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP,. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22: 133 -53.
15. Engelfriet CP, Reesink HW, Blajchman MA, Muylle L, Kjeldsen-Kragh J, Kekomaki R, Yomtovian R, Hocker P, Stiegler G, Klein HG, Soldan K, Barbara J, Slopecki A, Robinson A, Seyfried H,. Bacterial contamination of blood components. Vox Sang 2000; 78: 59 -67.
16. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877 -85.
17. Goodrich RP, Edrich RA, Goodrich LL, Scott CA, Manica KJ, Hlavinka DJ, Hovenga DH, Hansen ET, Gampp D, Keil SD, Gilmour DI, Li J, Martin CB, Platz MS,. The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine. In:, Silva E, Edwards AM, editors. Comprehensive series in photochemistry and photobiology. Vol 6. Flavins: photochemistry and photobiology. Cambridge, UK: The Royal Society of Chemistry; 2006. p. 83 -113.
18. Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90: 85 -91.
19. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131 -7.
20. Rentas F, Harman R, Gomez C, Salata J, Childs J, Silva T, Lippert L, Montgomery J, Richards A, Chan C, Jiang J, Reddy H, Li J, Goodrich R,. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007; 47: 240 -7.
21. Goodrich RP, Gilmour D, Hovenga N, Keil SD,. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205 -16.
22. Mintz PD, Wehrli G,. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009; 44: 205 -11.
23. Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R,. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/-double knockout mice. Transfusion 2006; 46: 1553 -60.
24. Fast LD, DiLeone G, Li J, Goodrich R,. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642 -8.
25. Asano H, Lee CY, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM III,. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174 -82.
26. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335 -41.
27. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685 -92.
28. Ambruso DR, Thurman G, Marschner S, Goodrich RP,. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 2009; 49: 2631 -6.
29. Andreu G, Vasse J, Tardivel R, Semana G,. Platelet transfusion: products, indications, does, threshold and efficacy. Transfus Clin Biol 2009; 16: 118 -33.
30. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207 -14.
31. TRAP. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861 -9.
32. McCulloch CE, Searle SR, Nehaus JM,. Generalized, linear and mixed models. 2nd ed. New York: John Wiley & Sons Inc; 2008. p. 1.
33. Wu L,. Mixed effects models for complex data. Boca Raton (FL): Chapman and Hall/CRC; 2009. p. 1 -431.
34. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10 -23.
35. Therneau TM, Grambsch PM,. Modeling survival data: extending the Cox model. 1st, 2nd Printing ed. New York: Springer-Verlag; 2000. p. 1 -350.
36. Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, Michelson AD, Gagnon DR, Valeri C,. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 117: 172 -85.
37. Spector JI, Skrabut EM, Valeri CR,. Oxygen consumption, platelet aggregation and release reactions in platelets freeze-preserved with dimethylsulfoxide. Transfusion 1977; 17: 99 -109.
38. Melaragno AJ, Carciero R, Feingold H, Talarico L, Weintraub L, Valeri CR,. Cryopreservation of human platelets using 6% dimethyl sulfoxide and storage at -80 degrees C. Effects of 2 years of frozen storage at -80 degrees C and transportation in dry ice. Vox Sang 1985; 49: 245 -58.
39. Owens M, Cimino C, Donnelly J,. Cryopreserved platelets have decreased adhesive capacity. Transfusion 1991; 31: 160 -3.
40. Shepherd KM, Sage RE, Barber S, OBrien E,. Platelet cryopreservation. 1. In vitro aggregation studies. Cryobiology 1984; 21: 39 -43.
41. Dullemond-Westland AC, Van Prooijen HC, Riemens MI, Akkerman JW,. Cryopreservation disturbs stimulus-response coupling in a platelet subpopulation. Br J Haematol 1987; 67: 325 -33.
42. Valeri CR,. Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med 1974; 290: 353 -8.
43. Schiffer CA, Aisner J, Wiemik PH,. Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med 1978; 299: 7 -12.
44. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P,. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958 -67.
45. Bishop JF, Matthews JP, Yuen K, McGrath K, Wolf MM, Szer J,. The definition of refractoriness to platelet transfusions. Transfus Med 1992; 2: 35 -41.
46. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN,. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42: 556 -66.
47. Heddle NM, Cook RJ, Blajchman MA, Barty RL, Sigouin CS, Boye DM, Nelson EJ, Kelton JG,. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion 2005; 45: 896 -903.
48. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G,. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dellAdulto. N Engl J Med 1997; 337: 1870 -5.
49. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA,; SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard-and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564 -73.